8-KShareholder Matters

REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 15, 2016)

Filed June 15, 2016For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 15, 2016, detailing the results of its Annual Meeting of Shareholders held on June 10, 2016. The primary focus of the report is the shareholder votes on key corporate governance matters. Investors can take comfort in the overwhelming approval of the proposed director nominees and the ratification of the independent auditor, indicating strong shareholder support for the company's leadership and financial oversight.

Key Highlights

  • 1Shareholders overwhelmingly elected all three Class I director nominees: Michael S. Brown, M.D., Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., to serve until the 2019 Annual Meeting.
  • 2The election of directors saw strong affirmative votes, with each nominee receiving over 100 million 'For' votes, underscoring shareholder confidence in the current board.
  • 3The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016, was overwhelmingly ratified by shareholders.
  • 4The ratification of the auditor received substantial support, with over 116 million 'For' votes, demonstrating shareholder trust in the company's financial reporting and audit process.
  • 5The report provides detailed voting results, including 'For,' 'Against,' 'Abstain,' and 'Broker Non-Votes' for each proposal.
  • 6No unexpected or adverse proposals were presented or voted upon, suggesting a routine annual shareholder meeting from a governance perspective.

Frequently Asked Questions

The main outcomes were the election of Class I directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2016. Both proposals received overwhelming shareholder approval.

Shareholders overwhelmingly elected the three Class I director nominees: Michael S. Brown, M.D., Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D. Each nominee received a substantial majority of 'For' votes, indicating strong shareholder confidence in the board's leadership.

Yes, the appointment of PricewaterhouseCoopers LLP as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2016, was overwhelmingly ratified by shareholders, with a large majority voting in favor.

No, the voting results presented in this 8-K are highly positive and indicate strong shareholder support for both the company's board of directors and its financial oversight. There are no apparent concerns or negative outcomes from the shareholder votes.